There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Myostatin is an endogenous negative regulator of muscle growth and a novel target for muscle diseases . We conducted a safety trial of a neutralizing antibody to myostatin , MYO‐029 , in adult muscular dystrophies ( Becker muscular dystrophy , facioscapulohumeral dystrophy , and limb‐girdle muscular dystrophy )
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .